These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 6613492)

  • 1. No acute effect of pimozide on the plasma GH levels in acromegaly.
    Nortier JW; Croughs RJ; Donker GH; Thijssen JH; Schwarz F
    Acta Endocrinol (Copenh); 1983 Aug; 103(4):461-8. PubMed ID: 6613492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the acute administration of haloperidol and pimozide on plasma GH levels in acromegaly.
    Carmina E; Lo Coco R; Lanzara P; Jannì A
    Acta Endocrinol (Copenh); 1979 Aug; 91(4):609-15. PubMed ID: 115193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly.
    Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ; Liuzzi A
    Acta Endocrinol (Copenh); 1983 Aug; 103(4):446-50. PubMed ID: 6310918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contradictory clinical implications between paradoxical growth hormone responses to thyrotropin-releasing hormone and those to vasoactive intestinal peptide and luteinizing hormone-releasing hormone in acromegaly.
    Watanobe H; Tamura T; Sasaki S; Takebe K
    Neuropeptides; 1993 Dec; 25(6):363-75. PubMed ID: 8127416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in plasma GH levels and clinical activity during bromocriptine therapy in acromegaly. The value of predictive tests.
    Nortier JW; Croughs RJ; Donker GH; Thijssen JH; Schwarz F
    Acta Endocrinol (Copenh); 1984 Jun; 106(2):175-83. PubMed ID: 6145276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term bromocriptine therapy and predictive tests in acromegaly.
    Karashima T; Kato K; Nawata H; Ikuyama S; Ibayashi H; Okamura K; Shiroozu A; Nakashima T; Fujishima M
    Endocrinol Jpn; 1986 Apr; 33(2):163-7. PubMed ID: 3093202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic and clinical studies on patients with acromegaly treated with bromocriptine over 22 months.
    Schwinn G; Dirks H; McIntosh C; Köbberling J
    Eur J Clin Invest; 1977 Apr; 7(2):101-7. PubMed ID: 404154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CV 205-502 in acromegaly.
    Chiodini PG; Attanasio R; Cozzi R; Dallabonzana D; Oppizzi G; Orlandi P; Strada S; Liuzzi A
    Acta Endocrinol (Copenh); 1993 May; 128(5):389-93. PubMed ID: 8100375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of long-term treatment with bromocriptine on the growth hormone response to galanin in patients with acromegaly.
    Giustina A; Doga M; Bussi AR; Licini M; Schettino M
    Acta Endocrinol (Copenh); 1993 Feb; 128(2):131-5. PubMed ID: 7680832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly.
    Arihara Z; Sakurai K; Yamashita R; Niitsuma S; Ueno T; Yamamura N; Yamada S; Inoshita N; Takahashi K
    Tohoku J Exp Med; 2014 Oct; 234(2):129-35. PubMed ID: 25253414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone inhibitory and stimulatory actions of L-dopa in patients with acromegaly.
    Hanew K; Sasaki A; Sato S; Goh M; Yoshinaga K
    J Clin Endocrinol Metab; 1987 Feb; 64(2):255-60. PubMed ID: 3793848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lisuride hydrogen maleate: evidence for a long lasting dopaminergic activity in humans.
    Liuzzi A; Chiodini PG; Oppizzi G; Botalla L; Verde G; De Stefano L; Colussi G; Gräf KJ; Horowski R
    J Clin Endocrinol Metab; 1978 Feb; 46(2):196-202. PubMed ID: 108287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effect of an ergoline derivative, methergoline, on growth hormone and prolactin levels in acromegalic patients.
    Chiodini PG; Liuzzi A; Muller EE; Botalla L; Cremascoli G; Oppizzi G; Verde G; Silvestrini F
    J Clin Endocrinol Metab; 1976 Aug; 43(2):356-63. PubMed ID: 950367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the new ergot derivative terguride on plasma PRL and GH levels in patients with pathological hyperprolactinemia or acromegaly.
    Dallabonzana D; Liuzzi A; Oppizzi G; Verde G; Chiodini PG; Dorow R; Horowski R
    J Endocrinol Invest; 1985 Apr; 8(2):147-51. PubMed ID: 4031381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in growth hormone (GH) secretion induced by human pancreatic GH releasing hormone-44 in acromegaly: a comparison with thyrotropin-releasing hormone and bromocriptine.
    Chiodini PG; Liuzzi A; Dallabonzana D; Oppizzi G; Verde GG
    J Clin Endocrinol Metab; 1985 Jan; 60(1):48-52. PubMed ID: 3917270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas.
    Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ
    J Clin Endocrinol Metab; 1985 Jun; 60(6):1148-53. PubMed ID: 3923021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients.
    Ferrari C; Paracchi A; Romano C; Gerevini G; Boghen M; Barreca A; Fortini P; Dubini A
    Clin Endocrinol (Oxf); 1988 Nov; 29(5):467-76. PubMed ID: 2908102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of acromegalic patients with a good response to octreotide, a somatostatin analogue.
    Yang IM; Woo JT; Kim SW; Kim JW; Kim YS; Choi YK
    Clin Endocrinol (Oxf); 1995 Mar; 42(3):295-301. PubMed ID: 7758235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bromocriptine therapy in acromegaly: use in patients resistant to conventional therapy and effect on serum levels of somatomedin C.
    Moses AC; Molitch ME; Sawin CT; Jackson IM; Biller BJ; Furlanetto R; Reichlin S
    J Clin Endocrinol Metab; 1981 Oct; 53(4):752-8. PubMed ID: 6793607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of dopamine on plasma growth hormone and prolactin levels in normal and acromegalic subjects.
    Camanni F; Massara F; Belforte L; Rosatello A; Molinatti GM
    J Clin Endocrinol Metab; 1977 Mar; 44(3):465-73. PubMed ID: 838847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.